Jiacong Guo
Founder of BeiCell Therapeutics
United States
Overview
Work Experience
Co-Founder
2022 - Current
Cofounder of BeiCell Therapeutics, incubated by BioTrack Capital, a revolutionary cell therapy company stemming from Prof. Hongkui Deng’s lab at Peking University, aiming to provide completely off-the-shelf cell therapy for cancer, autoimmune diseases treatment and regenerative medicine.
Executive Director
2022
Healthcare Investment with 1.5B USD(10B RMB)AUM Primarily focused on biotech& pharmaceutical companies in early growth stage Fund raising, deal sourcing, due diligence, post-investment management and exit Directed the investment of: Asieris(SH:688176) BioNova,LaNova,Shanton,Innogen,Pyrotech,OnCusp, Abogen, Gritscience, Brise Parcitipated in the investment of: Exegenesis, OBio
Vice President
2019 - 2021
Member Board of Directors
2024
A platform company with magic power in Antibody Engineering consistently generating assets for BD or New-Co potential targeting all kinds of severe diseases
Board Member
2021
OnCusp Therapeutics is a biopharmaceutical company turning cutting-edge research assets into innovative oncology treatments.
Raised $125,000,000.00 from F-Prime Capital, Novo Holdings, Catalio Capital Management, OrbiMed, Sofinnova Investments, BioTrack Capital, CJNV BioVentures, Marshall Wace, Blackbird Ventures and Forge Life Science Partners.
Board Member
2020
An innovative biotech company which develops first-in-class drugs for patients suffering from metabolic diseases such as gout, pruritis, etc
Member Of The Supervisory Board
2020 - 2023
A leading biopharma which specializes in developing long lasting human GLP-1RA drugs for Type 2 Diabetes, Overweight and Cardiovascular patients
Assistant Director at CEO Office
2018 - 2019
Corporate Strategy and Investment Portofolio company: NASDAQ-listed company Inhibrx(INBX) Virtuoso
Investment Intern
2018 - 2018
Performed Due Diligence on 20+ projects within 3 months
Research Scientist
2017 - 2018
Worked in the core team who developed the first anti-PD1 antibody in the world-Nivolumab(trade name: Opdivo) Novel T cell immuno-oncology target discovery and mechanism of action study Monoclonal antibody screening and validation by functional assays Stable cell line generation by lentiviral transduction and CRISPR Diagnostic biomarker discovery& validation for IHC Pathology research
Bristol-Myers Squibb engages in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals.
Raised $23,580,000,000.00 from RA Capital Management, OUP (Osage University Partners), Aperture Venture Partners, Greg Bailey, Connecticut Innovations, Knoll Capital Management, Vivo Capital, Venrock, Litmore Capital and Carl Icahn.
Research Assistant
2011 - 2017
Therapeutic Monoclonal Antibody Development Tumor Microenvironment Research